CNSY CERENOME, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1095981 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-32.9%
TTM net income YoY-47.4%
TTM EPS YoY143.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-832.6%
Net margin-859.5%
FCF margin-813.5%
EBITDA margin-817.7%
Returns
ROE-1,468.0%
ROA-196.4%
ROIC (approx.)—
Asset turnover0.23x
Leverage & solvency
Liabilities / assets107.6%
Debt / equity—
Current ratio0.61x
Interest coverage-815.92x
Cash quality & payout
Operating cash flow / net income0.90x
Accruals ratio-19.6%
Payout ratio—
Capex / revenue39.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $5.21M | $5.82M | $4.91M | — | — |
| R&D expense | $8.38M | $10.58M | $9.69M | $9.70M | $5.32M |
| SG&A expense | $12.13M | $9.94M | $8.54M | $10.24M | $6.85M |
| Operating income | -$15.30M | -$14.70M | -$13.32M | -$19.71M | -$12.49M |
| Interest expense | $548,000 | $179,000 | $395,000 | $711,000 | $932,000 |
| Pretax income | -$22.39M | -$12.98M | — | — | — |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$22.39M | -$12.98M | -$13.32M | -$20.27M | -$13.40M |
| EBITDA | -$14.85M | -$13.82M | -$12.69M | -$19.09M | -$12.10M |
| EPS (basic) | -0.29 | -1.95 | -4.24 | -11.58 | -1.11 |
| EPS (diluted) | -0.29 | -2.34 | -4.24 | -11.58 | -1.11 |
| Weighted avg. shares (diluted) | 77.80M | 7.70M | 3.14M | 1.75M | 12.09M |
| Balance sheet | |||||
| Cash & equivalents | $4.26M | $76,000 | $8.55M | $18.12M | $18.40M |
| Short-term investments | $4.36M | $3.53M | — | — | — |
| Current assets | $14.85M | $5.26M | $9.83M | $21.82M | $19.72M |
| PP&E, net | $257,000 | $448,000 | $906,000 | $1.32M | $1.48M |
| Goodwill | $372,000 | $372,000 | $372,000 | $372,000 | $372,000 |
| Intangibles | $333,000 | $469,000 | $42,000 | — | — |
| Total assets | $16.32M | $6.63M | $11.39M | $23.87M | $21.98M |
| Current liabilities | $12.31M | $15.55M | $10.73M | $11.85M | $5.87M |
| Short-term debt | — | — | $3.98M | $1.61M | $1.61M |
| Long-term debt | — | — | — | $3.79M | $5.00M |
| Total debt | — | — | — | $5.39M | $6.61M |
| Total liabilities | $12.33M | $15.58M | $12.74M | $17.42M | $11.14M |
| Shareholders' equity | $4.00M | -$8.95M | -$1.35M | $6.45M | $10.84M |
| Net debt | — | — | — | -$12.73M | -$11.79M |
| Shares outstanding | 5.55M | 5.90M | 4.44M | 2.24M | 15.51M |
| Cash flow statement | |||||
| Operating cash flow | -$20.77M | -$10.55M | -$12.85M | -$12.97M | -$10.28M |
| Capital expenditure | $67,000 | $146,000 | $160,000 | — | — |
| Free cash flow | -$20.84M | -$10.70M | -$13.01M | — | — |
| Investing cash flow | -$854,000 | -$4.11M | -$160,000 | -$759,000 | -$82,000 |
| Financing cash flow | $30.31M | $6.19M | $3.44M | $13.45M | $20.42M |
| Depreciation & amortization | $445,000 | $872,000 | $628,000 | $619,000 | $395,000 |
| Stock-based compensation | $1.54M | $550,000 | $569,000 | $606,000 | $606,000 |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.